Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Conjunctival Redness
Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Conjunctival Redness
Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Conjunctival Redness
Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Ciliary Redness
Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Ciliary Redness
Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Ciliary Redness
Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Episcleral Redness
Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Episcleral Redness
Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Episcleral Redness
Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Chemosis
Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Chemosis
Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Chemosis
Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Eyelid Swelling
Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Eyelid Swelling
Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Eyelid Swelling
Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Tearing
Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Tearing
Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Tearing
Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Rhinorrhea
Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Rhinorrhea
Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Rhinorrhea
Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Nasal Pruritis
Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Nasal Pruritis
Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Nasal Pruritis
Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Ear or Palate Pruritis
Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Ear or Palate Pruritis
Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Ear or Palate Pruritis
Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Nasal Congestion
Nasal congestion evaluated by the subject (0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Nasal Congestion
Nasal congestion evaluated by the subject (0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Nasal Congestion
Nasal congestion evaluated by the subject 0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 3.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Conjunctival Redness
Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Conjunctival Redness
Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Conjunctival Redness
Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Ciliary Redness
Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Ciliary Redness
Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Ciliary Redness
Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Episcleral Redness
Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Episcleral Redness
Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Episcleral Redness
Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Chemosis
Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Chemosis
Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Chemosis
Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Eyelid Swelling
Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Eyelid Swelling
Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Eyelid Swelling
Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Tearing
Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Tearing
Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Tearing
Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Rhinorrhea
Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Rhinorrhea
Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Rhinorrhea
Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Nasal Pruriti
Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Nasal Pruritis
Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Nasal Pruritis
Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Ear or Palate Pruritis
Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Ear or Palate Pruritis
Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Ear or Palate Pruritis
Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Nasal Congestion
Nasal congestion pruritis evaluated by the subject (0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Nasal Congestion
Nasal congestion pruritis evaluated by the subject (0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 4b.
Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Nasal Congestion
Nasal congestion pruritis evaluated by the subject (0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 4b.